Compare Stocks

→ The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKUS Akouos	$13.29	$13.29	$2.32 ▼ $13.60	$490.88M	-0.55	344,411 shs	440 shs
ANIP ANI Pharmaceuticals	$65.43 -1.1%	$65.34	$36.99 ▼ $70.81	$1.38B	0.79	137,701 shs	83,439 shs
ETNB 89bio	$8.58 -3.8%	$11.07	$6.57 ▼ $22.93	$816.99M	1.04	1.23 million shs	871,176 shs
FBRX Forte Biosciences	$0.71 -4.1%	$0.70	$0.38 ▼ $1.15	$25.84M	0.48	32,865 shs	14,300 shs
TXMD TherapeuticsMD	$1.92 +2.1%	$2.23	$1.86 ▼ $4.73	$21.68M	1.03	21,261 shs	14,824 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKUS Akouos	0.00%	0.00%	0.00%	0.00%	0.00%
ANIP ANI Pharmaceuticals	-1.07%	-0.08%	-5.99%	+20.50%	+74.11%
ETNB 89bio	-3.81%	-6.33%	-24.34%	-17.82%	-44.47%
FBRX Forte Biosciences	-3.87%	-4.05%	0.00%	+3.59%	-32.38%
TXMD TherapeuticsMD	+1.59%	+1.59%	-16.16%	-16.52%	-46.81%

Did You Get Your Free Bitcoin Yet? (Ad)

And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

>> Register right here

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKUS Akouos	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	4.7342 of 5 stars	2.5	5.0	0.0	3.3	2.3	3.3	3.1
ETNB 89bio	1.9121 of 5 stars	4.4	1.0	0.0	0.0	1.9	1.7	0.0
FBRX Forte Biosciences	3.287 of 5 stars	3.3	5.0	0.0	0.0	2.2	2.5	1.3
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKUS Akouos	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	3.00	Buy	$80.00	22.27% Upside
ETNB 89bio	2.71	Moderate Buy	$29.00	238.00% Upside
FBRX Forte Biosciences	2.50	Moderate Buy	$2.75	287.32% Upside
TXMD TherapeuticsMD	2.00	Hold	N/A	N/A

Current Analyst Ratings

Latest TXMD, AKUS, ANIP, ETNB, and FBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/23/2024	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00
4/22/2024	ETNB 89bio	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$30.00
4/8/2024	FBRX Forte Biosciences	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$2.75
4/5/2024	ETNB 89bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$29.00
3/27/2024	ETNB 89bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
3/15/2024	ANIP ANI Pharmaceuticals	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$80.00
3/13/2024	ETNB 89bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
3/6/2024	ETNB 89bio	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$29.00 ➝ $37.00
3/5/2024	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $77.00
3/5/2024	ETNB 89bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
3/4/2024	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$73.00 ➝ $83.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKUS Akouos	N/A	N/A	N/A	N/A	$4.90 per share	N/A
ANIP ANI Pharmaceuticals	$486.82M	2.83	$6.40 per share	10.23	$21.13 per share	3.10
ETNB 89bio	N/A	N/A	N/A	N/A	$5.75 per share	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$0.97 per share	N/A
TXMD TherapeuticsMD	$1.30M	17.01	N/A	N/A	$2.77 per share	0.69

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKUS Akouos	-$86.67M	-$2.62	N/A	N/A	N/A	N/A	-45.09%	-36.86%	N/A
ANIP ANI Pharmaceuticals	$18.78M	$0.84	77.89	15.80	N/A	3.86%	18.06%	8.38%	5/10/2024 (Confirmed)
ETNB 89bio	-$142.19M	-$2.01	N/A	N/A	N/A	N/A	-31.01%	-27.84%	5/2/2024 (Estimated)
FBRX Forte Biosciences	-$31.48M	-$1.04	N/A	N/A	N/A	N/A	-94.27%	-81.36%	5/20/2024 (Estimated)
TXMD TherapeuticsMD	-$10.28M	N/A	0.00	∞	N/A	N/A	-25.54%	-14.87%	5/20/2024 (Estimated)

Latest TXMD, AKUS, ANIP, ETNB, and FBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/10/2024	N/A	ANIP ANI Pharmaceuticals	$0.9650	N/A	-$0.9650	N/A	N/A	N/A
3/18/2024	Q4 2023	FBRX Forte Biosciences	N/A	-$0.04	-$0.04	-$0.04	N/A	N/A
2/29/2024	Q4 2023	ANIP ANI Pharmaceuticals	$0.58	$0.78	+$0.20	$1.52	$123.02 million	$131.65 million
2/29/2024	Q4 2023	ETNB 89bio	-$0.49	-$0.50	-$0.01	-$0.50	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKUS Akouos	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKUS Akouos	N/A	17.30	17.30
ANIP ANI Pharmaceuticals	0.66	3.57	2.81
ETNB 89bio	0.05	20.04	20.04
FBRX Forte Biosciences	N/A	10.45	10.45
TXMD TherapeuticsMD	N/A	1.72	1.72

Ownership

Institutional Ownership

Company	Institutional Ownership
AKUS Akouos	N/A
ANIP ANI Pharmaceuticals	76.05%
ETNB 89bio	N/A
FBRX Forte Biosciences	77.63%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
AKUS Akouos	4.80%
ANIP ANI Pharmaceuticals	12.70%
ETNB 89bio	4.40%
FBRX Forte Biosciences	10.53%
TXMD TherapeuticsMD	1.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AKUS Akouos	103	36.94 million	35.16 million	Not Optionable
ANIP ANI Pharmaceuticals	642	21.08 million	18.40 million	Optionable
ETNB 89bio	70	95.22 million	91.04 million	Optionable
FBRX Forte Biosciences	9	36.40 million	32.56 million	Optionable
TXMD TherapeuticsMD	1	11.53 million	11.39 million	Optionable

TXMD, AKUS, ANIP, ETNB, and FBRX Headlines

Source	Headline
	TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com americanbankingnews.com - April 19 at 2:14 AM
	TherapeuticsMD gets grant for progesterone formulation for oral administration with reduced dosage pharmaceutical-technology.com - April 18 at 9:36 AM
	TherapeuticsMD Announces Full Year 2023 Financial Results businesswire.com - March 29 at 4:00 PM
	TherapeuticsMD gets grant for progesterone formulations with reduced dosage for oral administration pharmaceutical-technology.com - March 28 at 11:17 AM
	25 Countries With Highest Abortion Rates msn.com - March 12 at 3:55 PM
	TherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo Finance sg.finance.yahoo.com - March 10 at 1:13 PM
	TherapeuticsMD Inc TXMD morningstar.com - December 29 at 5:48 PM
	Daily Markets: Today Brings Producer Prices, Retail Sales Data nasdaq.com - November 15 at 9:54 AM
	TherapeuticsMD to Consider Strategic Alternatives marketwatch.com - November 14 at 7:04 PM
	TherapeuticsMD exploring strategic alternatives for company msn.com - November 14 at 6:27 PM
	TherapeuticsMD Announces Third Quarter 2023 Financial Results finance.yahoo.com - November 14 at 6:27 PM
	Boca Raton-based prescription service announces layoffs, says a third of workforce could be cut bizjournals.com - October 4 at 5:11 PM
	TherapeuticsMD Inc. stock falls Wednesday, underperforms market marketwatch.com - September 20 at 6:46 PM
	TherapeuticsMD Inc. stock outperforms market despite losses on the day marketwatch.com - August 15 at 7:00 PM
	TherapeuticsMD Announces Second Quarter 2023 Financial Results finance.yahoo.com - August 14 at 7:50 AM
	Micron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of Directors finance.yahoo.com - August 9 at 8:38 PM
	TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors marketwatch.com - July 5 at 6:51 PM
	TherapeuticsMD Rejected by FDA, Delay Could Be Fatal thestreet.com - July 4 at 7:28 AM
	TherapeuticsMD Inc. [TXMD] Investment Appeal on the Rise knoxdaily.com - June 19 at 3:12 PM
	TherapeuticsMD: From Fallen And Forgotten To Cash Cow seekingalpha.com - May 23 at 9:28 AM
	TherapeuticsMD Announces First Quarter 2023 Financial Results finance.yahoo.com - May 15 at 4:19 PM
	NeuroBo Pharmaceuticals (NRBO) Appoints Mark A. Glickman to its ... - StreetInsider.com news.google.com - May 14 at 10:42 AM
	NeuroBo Pharmaceuticals Appoints Mark A. Glickman to its Board of ... - citybiz news.google.com - May 13 at 7:51 PM
	NeuroBo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to its Board of Directors - Yahoo Finance news.google.com - May 12 at 8:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akouos

NASDAQ:AKUS

Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.

ANI Pharmaceuticals

NASDAQ:ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

89bio

NASDAQ:ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Forte Biosciences

NASDAQ:FBRX

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

TherapeuticsMD

NASDAQ:TXMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial